ArticleEMBO molecular medicine2014
TORC2-a new player in genome stability.
Article in EMBO molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- TORC2 inactivation promotes heterochromatin formation in rDNA and prolongs viability of quiescent fission yeast cells.Communications biology · 2025Article
- Acrylamide-mediated errors in the cell cycle regulation are associated with altered TORC2 signaling in Schizosaccharomyces pombe.Scientific reports · 2025Article
- Compensatory evolution to DNA replication stress is robust to nutrient availability.Molecular systems biology · 2025Article
- Nickel induced cell impairments are negatively regulated by the Tor1 kinase in Schizosaccharomyces pombe.World journal of microbiology & biotechnology · 2021Article
- Review
- Landscape of clinically actionable mutations in breast cancer 'A cohort study'.Translational oncology · 2021Article
- Review
- An optogenetic system to control membrane phospholipid asymmetry through flippase activation in budding yeast.Scientific reports · 2020Article
- Review
- PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.Cell death and differentiation · 2019Article
- White shark genome reveals ancient elasmobranch adaptations associated with wound healing and the maintenance of genome stability.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- The application of gene marker-assisted selection and proteomics for the best meat quality criteria and body measurements in Qinchuan cattle breed.Molecular biology reports · 2018Review
- Systematic analysis of complex genetic interactions.Science (New York, N.Y.) · 2018Article
- Inhibiting 4EBP1 in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Review
- Review
- The effects of TORC signal interference on lipogenesis in the oleaginous yeast Trichosporon oleaginosus.BMC biotechnology · 2017Article
- Multiple crosstalk between TOR and the cell integrity MAPK signaling pathway in fission yeast.Scientific reports · 2016Article
- Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Gad8 Protein Is Found in the Nucleus Where It Interacts with the MluI Cell Cycle Box-binding Factor (MBF) Transcriptional Complex to Regulate the Response to DNA Replication Stress.The Journal of biological chemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The inhibition of the central growth regulatory kinase TOR, which participates in two complexes, TORC1 and TORC2, has been a focus of metabolic and cancer studies for many years. Most studies have dealt with TORC1, the canonical target of rapamycin, and the role of this complex in autophagy, protein synthesis, and cell growth control. Recent work on TORC2 in budding and fission yeast species points to a conserved role of this lesser-known TOR complex in the survival of DNA damage. In budding yeast, TORC2 controls lipid biosynthesis and actin cytoskeleton through downstream AGC kinases, which are now, surprisingly, implicated in the survival of oxidative DNA damage. Preliminary data from mTORC2 modulation in cancer cells suggest that an extension to human chemotherapy is worth exploring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.